Markers of cholesterol absorption and synthesis predict the low-density lipoprotein cholesterol response to atorvastatin

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 4, 2010, Pages 396-401

  Hoenig, Michel R ^a   Walker, Philip J ^a   Gurnsey, Christine ^b   Beadle, Karen ^b   Johnson, Leslie ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

cholesterol; cholesterol metabolism; lipids; personalized medicine; statin

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTANOL; CHOLESTEROL; DESMOSTEROL; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SITOSTEROL;

AGED; ARTICLE; BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ABSORPTION; AGED; BIOLOGICAL MARKERS; CHOLESTANOL; CHOLESTEROL; CHOLESTEROL, LDL; DESMOSTEROL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; PROGNOSIS; PROSPECTIVE STUDIES; PYRROLES;

EID: 77958487586     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181f09bcb     Document Type: Article

References (22)

1. Robinson JG, Smith B, Maheshwari N, et al. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol. 2005;46:1855-1862.
2. Thompson GR, O'Neill F, Seed M, et al. Why some patients respond poorly to statins and how this might be remedied. Eur Heart J. 2002;23: 200-206.
3. Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46:1411-1416.
4. Thompson JF, Man M, Johnson KJ, et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 2005;5:352-358.
5. Thompson JF, Hyde CL, Wood LS, et al. Comprehensive whole genome and candidate gene analysis for response to statin therapy in TNT cohort. Circ Cardiovasc Genet. 2009;2:173-181.
6. Voora D, Shah SH, Reed CR, et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet. 2008;1:100-106.
7. Miettinen TA, Tilvis RS, Kesaniemi YA, et al. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol. 1990; 131:20-31.
8. Bjorkhem I, Miettinen T, Reihner E, et al. Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver. J Lipid Res. 1987;28:1137-1143.
9. Miettinen TA, Gylling H, Strandberg T, et al. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ. 1998;316: 1127-1130.
10. Miettinen TA, Strandberg TE, Gylling H. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler Thromb Vasc Biol. 2000;20:1340-1346.
11. 4S, randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
12. Miettinen TA, Gylling H. Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patients. Atherosclerosis. 2002;164:147-152.
13. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197-1206.
14. Hoenig MR, Rolfe BE, Campbell JH. Cholestanol: a serum marker to guide LDL cholesterol-lowering therapy. Atherosclerosis. 2006;184:247-254.
15. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
16. O'Keefe JH Jr, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142-2146.
17. Hoenig MR, Kostner KM, Read SJ, et al. Implications of the obesity epidemic for statin therapy: shifting cholesterol metabolism to a high synthesis and low dietary absorption state. Endocr Metab Immune Disord Drug Targets. 2007;7:153-166.
18. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
19. van Himbergen TM, Matthan NR, Resteghini NA, et al. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res. 2009;50:730-739.
20. Lakoski SG, Xu F, Vega GL, et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab. 2010;95:800-809.
21. Sarkkinen E, Korhonen M, Erkkila A, et al. Effect of apolipoprotein E polymorphism on serum lipid response to the separate modification of dietary fat and dietary cholesterol. Am J Clin Nutr. 1998;68:1215-1222.
22. Kesaniemi YA, Ehnholm C, Miettinen, TA. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest. 1987;80:578-581.